

Appendix: Supplementary tables

supplementary Table 1. Difference in CGI-I between the bumetanide group and the placebo group at month 3				
	Bumetanide (n=59)	Placebo (n=60)	Group Comparisons	
			Kruskal-Wallis chi-squared	p value
CGI-I			3.50	0.061
Responder	22(37.3%)	13(21.7%)		
Non-responder	37(62.7%)	47(78.3%)		
Data are n (%). CGI-I=Clinical Global Impressions-Improvement.				

supplementary Table 2. Characteristics of MRS quality control related parameters

Parameter	Baseline		Follow-up		Statistic					
	Placebo	Bumetanide	Placebo	Bumetanide	Baseline placebo vs Baseline Bumetanide		Follow-up placebo vs Follow-up Bumetanide		Baseline vs Follow-up	
					t/χ	p	t/χ	p	t/χ	p
Num. of images enter MRS Q.C. ^a	49	43	43	37						
FWHM (ppm)										
Before Q.C.	0.040 (0.019)	0.039 (0.015)	0.045 (0.022)	0.044 (0.021)	0.190	0.849	0.316	0.753	-1.726	0.086
Num. Passed Q.C.	39	34	29	27	0.004	0.951	0.290	0.590	1.994	0.158
SNR										
Before Q.C.	21.898 (4.214)	20.721 (6.482)	20.767 (5.259)	19.703 (5.093)	1.045	0.299	0.916	0.362	1.325	0.187
Num. Passed Q.C.	45	36	35	29	1.433	0.231	0.113	0.737	2.092	0.149
GABA SD%										
Before Q.C.	8.327 (1.345)	9.674 (5.498)	8.140 (0.941)	8.351 (1.338)	-1.661	0.100	-0.828	0.410	1.583	0.115
Num. Passed Q.C.	49	41	43	37	/	/	/	/	/	/
Num. Passed Q.C. of above three	37	30	28	24	0.382	0.537	0.001	0.981	1.229	0.268

a: at baseline, two subjects with MRS/MRI image scanned did not enter the MRS quality control steps, one of them was the subject who did not enter the mITT analysis, the other one with the MRS insula voxel placed on the opposite hemisphere. At follow-up stage, one subject with MRS/MRI image scanned didn't enter these QC steps, as the MRS voxel placed on the opposite hemisphere.

supplementary Table 3. Characteristics of Subjects passed and failed in MRS quality control steps

Variable	Baseline				Follow-up			
	Placebo	Bumetanide	t/ χ	p	Placebo	Bumetanide	t/ χ	p
N	49	43 ^a			43	37 ^b		
Age in years	4.03(0.87)	4.01(0.90)	0.132	0.896	3.93(0.78)	3.92(0.90)	0.064	0.949
Sex								
Female	9	7			8	7		
Male	40	36	0.069	0.792	35	30	0.001	0.971
CARS Total score	37.81(4.32)	38.44(3.59)	0.770	0.443	36.52(4.09)	36.23(3.35)	0.353	0.725
Comorbidity with DD/ID								
With DD/ID	31	31			27	28		
Without DD/ID	18	12	0.812	0.368	16	9	1.537	0.215

a: at baseline, two subjects with MRS/MRI image scanned did not enter the MRS quality control steps, one of them was the subject who did not enter the mITT analysis, the other one with the MRS insula voxel placed on the opposite hemisphere.

b: follow-up stage, one subjects with MRS/MRI image scanned didn't enter as the MRS voxel placed on the opposite hemisphere.

supplementary Table 4. Secondary clinical efficacy outcomes at month 3

	Mean (SD) at baseline		Mean change (SD) between baseline and month 3		p value	Perm. p value*	FDR adjusted p value*
	Bumetanide (n=59)	Placebo (n=60)	Bumetanide (n=59)	Placebo (n=60)			
ADOS							
Communication	6.41 (1.53)	6.17 (1.65)	0.46 (0.74)	0.20 (0.70)	0.0476	0.0473	0.2366
Social score	10.83 (1.96)	10.47 (2.22)	0.52 (0.76)	0.57 (1.45)	0.8406	0.8417	0.9140
Social + Communication	17.24 (3.28)	16.63 (3.40)	0.96 (1.11)	0.77 (1.40)	0.3853	0.3999	0.6664
Imagination	2.75 (1.29)	2.33 (1.24)	0.25 (0.72)	0.27 (0.75)	0.9230	0.9140	0.9140
Repetition	2.32 (1.44)	1.92 (1.33)	0.18 (0.86)	0.02 (0.86)	0.3194	0.3182	0.6664
RBS-R							
Stereotypy	3.39 (2.24)	2.97 (2.49)	0.75 (1.36)	0.67 (1.45)	0.7591	0.7574	0.7574
Self-injury	0.47 (0.86)	0.97 (1.38)	0.14 (0.57)	0.42 (1.08)	0.0789	0.0750	0.3732
Compulsive behavior	3.19 (2.13)	3.33 (2.36)	0.64 (1.30)	1.05 (1.69)	0.1450	0.1599	0.3732
Ritualistic behavior	3.78 (2.39)	3.77 (2.35)	0.66 (1.82)	0.90 (1.71)	0.4618	0.4808	0.6732
Sameness	3.19 (2.47)	3.42 (2.55)	1.05 (1.89)	0.95 (1.52)	0.7488	0.7474	0.7574
Restricted behavior	3.2 (2.22)	2.98 (1.96)	0.42 (1.54)	0.82 (1.50)	0.1620	0.1529	0.3732
Total	17.22 (7.99)	17.43 (8.12)	3.66 (4.90)	4.80 (5.25)	0.2238	0.2309	0.4041

The treatment effect of bumetanide was assessed by testing the significance of an interaction term of a mixed effect model. The interaction term was defined by treatment X time. The p-value of this interaction term was listed. *Perm. p value: P value for time × group interaction in a mixed effect model based on 3000 random permutations. ADOS= Autism Diagnostic Observation Schedule. RBS-R= Repetitive Behavior Scale-Revised.

supplementary Table 5. Secondary clinical efficacy outcome (SRS) at month 3

	Mean (SD) at baseline		Mean (SD) at month 3		Mean change (SD) between baseline and month 3		t value	p value	Perm. p value*
	Bumetanide (n=25)	Placebo (n=30)	Bumetanide (n=25)	Placebo (n=30)	Bumetanide (n=25)	Placebo (n=30)			
Total	88.12 (24.28)	85.27 (18.13)	76.96 (22.06)	83.93 (20.38)	11.16 (18.30)	1.33 (16.27)	-2.1073	0.0398	0.0460
Subscale 1	10.64 (2.93)	10.40 (3.12)	9.64 (2.81)	10.57 (3.50)	1.00 (3.28)	-0.17 (3.38)	-1.2911	0.2023	0.2109
Subscale 2	17.28 (4.13)	16.87 (4.04)	15.36 (4.44)	16.90 (5.57)	1.92 (4.46)	-0.03 (4.11)	-1.6889	0.0971	0.1010
Subscale 3	30.48 (9.72)	29.13 (7.56)	27.16 (8.82)	29.17 (7.93)	3.32 (8.09)	-0.03 (7.23)	-1.6227	0.1106	0.1136
Subscale 4	15.12 (4.77)	14.23 (4.06)	13.20 (4.66)	13.60 (3.37)	1.92 (4.11)	0.63 (3.55)	-1.2459	0.2183	0.2256
Subscale 5	14.60 (7.11)	14.63 (4.73)	11.60 (5.92)	13.70 (4.96)	3.00 (5.00)	0.93 (5.50)	-1.4462	0.1540	0.1423

The treatment effect of bumetanide was assessed by testing the significance of an interaction term of a mixed effect model.

The interaction term was defined by treatment X time.

The p-value of this interaction term was listed.

*Perm. p value: P value for time × group interaction in a mixed effect model based on 3000 random permutations.

supplementary Table 6. The NAA/Cr and GABA/Cr ratios at baseline and month 3

	Mean (SD) at baseline*		Mean (SD) at month 3		Mean change (SD) between baseline and month 3		t value	p value	Perm. p value
	Bumetanide (n=18)	Placebo (n=22)	Bumetanide (n=18)	Placebo (n=22)	Bumetanide (n=18)	Placebo (n=22)			
NAA/Cr	1.53 (0.10)	1.51 (0.10)	1.53 (0.13)	1.52 (0.09)	0.00 (0.11)	-0.01 (0.10)	-0.22	0.82	0.77
GABA/Cr	0.56 (0.09)	0.52 (0.09)	0.50 (0.09)	0.52 (0.06)	0.06 (0.09)	0.00 (0.08)	-2.02	0.05	0.04

*One subject who had qualified GABA/NAA measurement was excluded, due to the missing of edit-off spectrum

The treatment effect of bumetanide was assessed by testing the significance of an interaction term of a mixed effect model. The interaction term was defined by treatment X time.

The p-value and perm. p value (3000 random permutations) of this interaction term was listed.

supplementary Table 7. Difference in change of CARS total score between patients with polyuria and without polyuria in bumetanide group

	Mean change (SD) between baseline and month 3		t ₅₇	p value
	With Polyuria (n=40)	Without Polyuria (n=19)		
CARS total scores	2.26 (1.31)	2.16 (1.28)	-0.29	0.77

Shown are mean (SD). Group differences are evaluated with Welch's t test.

supplementary Table 8 Correlations between change in laboratory tests and CARS scores in two groups

CARS	blood potassium						blood uric acid					
	bumetanide (n=59)			placebo (n=60)			bumetanide (n=59)			placebo (n=60)		
	r	p value	t value	r	p value	t value	r	p value	t value	r	p value	t value
Total score	0.2776	0.1018	1.2177	0.0943	1.0000	0.4178	-0.0012	0.3254	-0.6506	0.0017	0.2704	1.1853
No. of items scored ≥ 3	-0.1491	0.9608	-0.6456	0.3467	0.8039	1.1255	-0.0007	0.6667	-0.4093	0.0025	0.4265	1.2705
Item 1	0.0450	0.4082	0.8445	-0.0497	0.4110	-0.7944	-0.0001	0.8039	-0.2551	-0.0001	0.8235	-0.2289
Item 3	0.0238	0.5915	0.4995	0.0664	0.5000	0.8429	-0.0002	0.5915	-0.4084	-0.0004	0.5915	-0.7837
Item 4	0.0272	0.7647	0.5296	-0.0115	0.8235	-0.1927	0.0001	1.0000	0.1238	0.0002	0.9020	0.5893
Item 5	0.0301	0.6429	0.6240	-0.0877	0.2281	-1.3144	0.0000	0.8627	0.0886	0.0000	0.7059	-0.1007
Item 7	0.0408	0.9020	0.7733	-0.0349	0.9412	-0.4334	0.0000	0.9608	0.0601	0.0002	1.0000	0.4749
Item 13	0.0376	0.8039	0.5638	0.0387	0.9412	0.5061	0.0007	0.5542	1.3525	0.0003	0.3223	0.6136

Shown are Pearson's correlation coefficients between the change in laboratory tests after treatment and the change in CARS scores.

supplementary Table 10. The GABA/NAA ratio at baseline and month 3

	Mean (SD) at baseline ^a		F value	p value	Mean (SD) at baseline ^b		F value	p value
	Bumetanide (n=30)	Placebo (n=37)			Bumetanide (n=18)	Placebo (n=23)		
GABA/NAA	0.42 (0.06)	0.52 (0.09)	0.12	0.73	0.43 (0.06)	0.41 (0.06)	1.77	0.19

^a Difference of data from two groups available after baseline quality control were examined.

^b Difference of data from two groups available after both baseline and follow-up quality control were examined.